🌟 At #HOPLive24 , Jane N. Winter, of Northwestern Feinberg School of Medicine and Lurie Cancer Center, described her study on pembrolizumab in #HodgkinLymphoma .
🎙️ 'We’re hoping to reduce the amount of chemotherapy,' she said.
🎧 Listen to the full podcast episode here: buff.ly/3UEWNHu
KN 189 and 407 - Pooled Analysis of Outcomes - Sergio Cifuentes Canaval
OncoDaily
oncodaily.com/67548.html
#Cancer #Chemotherapy #EGFR #Immunohistochemistry #UniversityOfMexico #NSCLC #OncoDaily #Oncology #Pembrolizumab
Why pembrolizumab does not work along with cisplatin based CTRT in head neck cancer ( keynote 412 ) But same pembrolizumab works in cervical cancer with CTRT ( Keynote A18 ) . Perspective by Dr Voortman for head neck cancer part in The Lancet Oncology What can be reasons? Different
Mientras el paciente no reciba su medicamento, hay #desabasto .
Pembrolizumab (clave del CNIS 010.000.6153.00) es un mAb utilizado en inmunoterapia del cáncer.
Desde el 2020, más de un centenar de oncólogos me han comentado el viacrucis que es obtener medicamentos biológicos.
KEYNOTE-057 trial: Pembrolizumab for BCG-unresponsive w/o CIS NMIBC ➡️12-month DFS 43.5%, 2-year DFS 34.9%. Treatment-related AE 73% (14% grade 3/4), 11% discontinued due to AEs. Incredible effort by team for their enduring efforts! #BladderCancer #ClinicalTrial #CancerResearch
Dr. Thomas Ichim Dr. Ichim,
That's why I think Nature medicine missed a trial in its list. I honestly think it is the most important trial of this year.
nature.com/articles/s4159…
Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma
Immunotherapy success #pembrolizumab depends on tumor microenviroment
$CRVS #ITKi #soquelitinib make a tumor hot, reinvigorates T-cells => better patient outcomes
-increases CD8+, Th1, IFNg, granzyme B
-reverses T-cell exhaustion, reduces PD1, Tim3, Lag3
thelancet.com/journals/lanon…
Check an article on patients who completed two years of #pembrolizumab for advanced NSCLC, highlighting high rates of KRAS mutation & PD-L1 expression, and a subset with brain metastases and treated oligoprogression.
Full article: bit.ly/3Qz1FNa
Just out in Therapeutic Advances in Medical Oncology our publication about pembrolizumab in advanced intimal sarcoma patients. Previous publications suggest an “immune-rich” TME, and a complex interplay between adaptive PD-L1 expression/MS-status/TLS may exist. University Health Network University of Toronto Sinai Health Moffitt Cancer Center
📢Pembrolizumab monotherapy for high-risk NMIBC without carcinoma in situ and unresponsive to BCG
KEYNOTE-057, cohort B
The Lancet Oncology
✅Primary endpoint ➡️12-month disease-free survival: 43·5% (95% CI 34·9–51·9)
🚨14% had grade 3 or 4 treatment-related AE
✅Potentially an
